2025 · 3rd Quarter (July 1 - Sep 30)

ACURX PHARMACEUTICALS, INC.

Filed by INNOVATIVE FEDERAL STRATEGIES, LLC.

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 20, 2025
Income: $30,000.00
Expenses: Not reported
Registrant: INNOVATIVE FEDERAL STRATEGIES, LLC
Client: ACURX PHARMACEUTICALS, INC.
Filing UUID: c87e40e9-eb55-42d1-b8a2-595a82e944de
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

BUD · Budget/Appropriations

H.R.4026/S.2572, Department of Defense Appropriations Bill, 2026, Title IV, all provisions related to biodefense preparedness. H.R.5304/S.2587, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations bill, Title II, all provisions related research and clinical trials for the development of antibiotics for infections caused by bacteria listed as priority pathogens.

Literal federal measure citations: H.R.4026, S.2572, H.R.5304, S.2587

DEF · Defense

H.R.3838/S.2296, National Defense Authorization Act, 2026, Title II, all provisions related to biodefense preparedness.

Literal federal measure citations: H.R.3838, S.2296

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.